Development of a Scalable and Practical Synthesis of AB928, a Dual A2a/A2b Receptor Antagonist
- 1 June 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (7) , 1254-1261
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targetsImmunological Reviews, 2017
- It’s a long way to the top (if you want to personalize immunotherapy)Journal for ImmunoTherapy of Cancer, 2017
- Immunosuppressive activities of adenosine in cancerCurrent Opinion in Pharmacology, 2016
- Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ CellsThe Journal of Immunology, 2011
- Extracellular adenosine triphosphate and adenosine in cancerOncogene, 2010
- Adenosine receptors in regulation of dendritic cell differentiation and functionBlood, 2008
- Adenosine-Mediated Inhibition of Cytotoxic Activity and Cytokine Production by IL-2/NKp46-Activated NK cells: Involvement of Protein Kinase A Isozyme I (PKA I)Immunologic Research, 2006
- Click Chemistry: Diverse Chemical Function from a Few Good ReactionsAngewandte Chemie International Edition, 2001
- Memory of Extracellular Adenosine A2A Purinergic Receptor-mediated Signaling in Murine T CellsJournal of Biological Chemistry, 1997
- Syntheses of 4,12-Dimethyl[2.2]metacyclophaneJournal of the American Chemical Society, 1961